Slingshot members are tracking this event:

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details FDA has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I). The SB-318 IND application is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-318-1502) designed to assess the safety, tolerability and potential efficacy of SB-318 in adults with varying severities of MPS I.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda Clearance, Ind, Zfn-media Genome, Sb-318, Sb-318-1502, Mucopolysaccharidosis Type I